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Abstract: We review the current status of the role and function of the mitochondrial DNA (mtDNA) in the etiology of 
autism spectrum disorders (ASD) and the interaction of nuclear and mitochondrial genes. High lactate levels reported in 
about one in five children with ASD may indicate involvement of the mitochondria in energy metabolism and brain 
development. Mitochondrial disturbances include depletion, decreased quantity or mutations of mtDNA producing defects 
in biochemical reactions within the mitochondria. A subset of individuals with ASD manifests copy number variation or 
small DNA deletions/duplications, but fewer than 20 percent are diagnosed with a single gene condition such as fragile X 
syndrome. The remaining individuals with ASD have chromosomal abnormalities (e.g., 15q11-q13 duplications), other 
genetic or multigenic causes or epigenetic defects. Next generation DNA sequencing techniques will enable better 
characterization of genetic and molecular anomalies in ASD, including defects in the mitochondrial genome particularly 
in younger children. 
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  Leo Kanner described autism in 1943 in 11 children 
manifesting withdrawal from human contact as early as age 
1 year postulating origins in prenatal life [1]. The Diagnostic 
and Statistical Manual of Mental Disorders IV-Text Revised 
(DSM-IV-TR) described autism as a complex 
neurobehavioral disorder characterized by deficiencies in 
social interaction, impaired communication skills and 
repetitive stereotypic behavior with onset prior to 3 years of 
age [2]. Several conditions including full-syndrome autism 
(Autistic Disorder), Asperger Syndrome and Pervasive 
Developmental Disorder Not Otherwise Specified (PDD-
NOS) are now grouped as Autism Spectrum Disorders 
(ASD) also known as Pervasive Developmental Disorders 
(PDDs) [2-4].  
  Symptoms of ASD usually begin in early childhood with 
evidence of delayed development before age 3 years. The 
American Academy of Pediatrics recommends autism 
screening for early identification and intervention by at least 
age 12 months and again at 24 months. Rating scales helpful 
in establishing the diagnosis are Autism Diagnostic 
Interview- Revised (ADI-R) and the Autism Diagnostic 
Observation Schedule (ADOS) in combination with clinical 
presentation [5, 6].  
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GENETIC CONTRIBUTIONS TO AUTISM SPECT-
RUM DISORDERS 
  The etiology of ASD is complex and encompasses the 
roles of genes, the environment (epigenetics) and the 
mitochondria. Mitochondria are cellular organelles that 
function to control energy production necessary for brain 
development and activity. Researchers are increasingly 
identifying mitochondrial abnormalities in young children 
with ASD since the most severe cases present early with 
features of ASD. Better awareness and more accurate and 
detailed genetic and biochemical testing are now available 
for the younger patient presenting with developmental delay 
or behavioral problems.  
  Epidemiologic and family studies suggest that genetic 
risk factors are present. Monogenic causes are identifiable in 
less than 20 percent of subjects with ASD. The remaining 
subjects have other genetic or multigenic causes and/or 
epigenetic influences which are environmental factors 
altering gene expression without changing the DNA 
sequence [7-10]. Epigenetic factors in ASD have been 
reviewed by Grafodatskaya et al. [11]. The recurrence risk 
for ASD varies by gender for the second child to be affected 
(4% if the first child affected is female and 7% if a male). 
The recurrence rate increases to 25-30% if the second child 
is also diagnosed with ASD. Studies have shown that among 
identical twins, if one child has ASD, then the other has a 60 
to 95% chance of being affected.  
  Fragile X syndrome and tuberous sclerosis are the most 
common single gene conditions associated with ASD.  The 
commonest chromosomal abnormality in non-syndromal   Mitochondria and Autism  Current Genomics, 2011, Vol. 12, No. 5    323
autism is duplication of the 15q11-q13 region, accounting 
for 5% of patients with autism. Large microdeletions in 
chromosome 16p11.2 and 22q regions account for another 
1% of cases [12]. The rapid rise in the incidence of ASD in 
the past 30 years, apart from improved identification, points 
to environmental factors acting on essentially unchanged 
genetic predispositions involving nuclear and mitochondrial 
DNA since de novo changes in genes are unlikely to occur so 
quickly. Specific genetic and cytogenetic conditions 
associated with ASD are summarized in a recent review [13].  
  The role and importance of genetic testing for individuals 
with ASD is well recognized [14] with various studies 
showing yields of 6% to 40% with newer testing methods 
[15, 16]. Early studies by Miles and Hillman [15] tested 94 
children clinically diagnosed with ASD and found that 6 of 
94 (6%) had identifiable genetic disorders. Herman et al.
[17] later found genetic causes in 7 of 71 (10%) subjects 
with ASD. Schaefer and Lutz [16] used a three- tier clinical 
genetic approach to identify causes in 32 clinically 
diagnosed children with ASD, and reported positive genetic 
findings in 13 subjects (40%). These included 5% with a 
high resolution chromosomal abnormality, 5% with fragile X 
syndrome, 5% with Rett syndrome (MECP2 gene defects in 
females), 3% with PTEN gene mutations in those with a 
head circumference > 2.5 SD, approximately 10% with other 
genetic syndromes (e.g., tuberous sclerosis) and 10% with 
small deletions or duplications identified using chromosomal 
microarrays. 
  High resolution chromosome analysis detects 3 to 5 
megabase-sized abnormalities; however, new technology 
using DNA or chromosomal microarrays can identify 
abnormalities 100 times smaller. Therefore, microdeletions 
and duplications may now be identified with microarrays in 
individuals with ASD who previously had normal 
cytogenetic testing. Children with ASD show a higher 
prevalence of microdeletions and duplications, particularly 
involving chromosome regions 1q24.2, 3p26.2, 4q34.2, 
6q24.3 and 7q35 including those with non-syndromal ASD 
[18]. Therefore, if cytogenetic analysis is negative in 
clinically diagnosed ASD, testing for microdeletions and 
duplications with newer techniques is warranted.  
  Shen and coworkers [19] studied genetic testing results 
from a cohort of 933 patients with ASD including G-banded 
karyotypes, fragile X testing and chromosomal microarrays. 
They reported abnormal karyotypes in 19 of 852 patients 
(2.2.%), abnormal fragile X testing in 4 of 861 patients 
(0.5%) and microarray identified deletions or duplications in 
154 of 848 patients (18.2%). Fifty-nine of 154 subjects 
(38.3%) were associated with known genomic disorder 
variants with possible significance to ASD. With the 
exception of recurrent deletions or duplications of 
chromosome 16p11.2 [20] and chromosome 15q13.2q13.3 
[21], most copy number changes were unique.  
 Wang  et al. [22] reported the results from a genome-wide 
association study of 3,101 subjects representing 780 families 
with affected children and a second cohort of 1,204 affected 
subjects along with 6,491 controls. All of their subjects were 
of European ancestry. They found a strong association with 
six nucleotide polymorphisms between cadherin 10 
(CDH10) and cadherin 9 (CDH9) genes. The latter two 
genes encode neuronal cell-adhesion molecules. These 
findings were replicated in two independent cohorts and 
demonstrate an association with susceptibility to ASD.  
 Sebat  et al. [23] studied 165 individuals with autism 
grouped into 118 simplex families without a family history 
of autism and 47 multiplex families with multiple affected 
siblings and compared them with control groups without 
autism. They reported that 10.2% (12 of 118) of simplex 
families showed copy number variants (CNVs), 2.6% (2 of 
77) with CNVs in individuals with autism from multiplex 
families and 1% (2 of 196) with CNVs among normally 
developing children. The majority of CNVs were of the 
deletion type. Thus, CNVs were significantly more common 
in the sporadic form of autism than in those with a family 
history due to single gene mutations not detectable by DNA 
deletion or duplication analysis. 
  As a result of research into nucleotide sequences, 
microdeletions and duplications in children with ASD can 
now be identified including syntaxin binding protein 5 
(STXBP5) and neuronal leucine rich repeat 1 (NLRR1) genes. 
Syntaxin 5 regulates synaptic transmission at the pre-
synaptic cleft and is known to inhibit synapse formation. 
Syntaxin 1 protein is increased in those with high 
functioning autism. The role of NLRR1 at the synaptic level 
is unknown but is thought to be related to neuronal growth 
[24].  
  An autism genome-wide copy number variation study 
reported by Glessner et al. [25] in a large cohort of ASD 
cases compared with controls showed that NRXN1  and 
CNTN4 genes play a role. They also described new 
susceptibility genes, NLGN1 and ASTN2  which encode 
neuronal cell-adhesion molecules and other genes involved 
in the ubiquitin pathways (UBE3A, PARK2, RFWD2 and 
FBXO40), two important gene networks expressed in the 
central nervous system. 
  Next generation DNA sequencing is currently underway, 
allowing for rapid and efficient detection of mutations at the 
nuclear and mitochondrial DNA (mtDNA) level in human 
investigations and becoming part of clinical workup. 
Heteroplasmy or the existence of multiple mtDNA types 
within cells of an individual, is detectable using standard 
molecular genetic techniques which focus on hypervariable 
regions of the mitochondrial genome. With high-throughput 
next generation sequencing of the complete human mtDNA, 
which is faster and more powerful, accurate detection of 
heteroplasmy can be made throughout the mitochondrial 
genome not just in the hypervariable regions located in the 
cytoplasm of the cell enabling the study of correlation with 
diseases.  
 Recently,  Li  et al. [26] sequenced the mitochondrial 
genome of 131 healthy individuals of European ancestry. 
They identified 37 heteroplasmies at 10% frequency or 
higher in 32 individuals and located at 34 different sites of 
the mtDNA indicating that variation commonly occurs in 
mtDNA. These variations may impact on energy levels and 
influence brain development and function. Next generation 
sequencing should provide novel insights into genome-wide 
aspects of mtDNA variation or heteroplasmy useful in the 
study of human disorders including autism.  324 Current Genomics, 2011, Vol. 12, No. 5 Dhillon et al.
  With a significant percentage of children with autism 
presenting with metabolic abnormalities (e.g., high lactate 
levels) and other biochemical disturbances, identification of 
mitochondrial disorders is critical for early treatment. Long 
standing mitochondrial dysfunction can lead to major health 
complications and damage. If identified early, mitochondrial 
disorders can be managed with improved longevity and 
quality of life. Medical intervention and therapies are now 
available to specifically target the biochemical defect in the 
mitochondria and to improve function and bioenergy 
utilization and diminish the neurological insults that would 
occur if left untreated.  
MITOCHONDRIAL ROLE IN AUTISM 
Metabolic Effects 
  Inborn errors of metabolism may contribute to at least 
5% of cases with ASD [27]. Deficiency of certain enzymes 
in metabolic disorders leads to an accumulation of 
substances that can cause toxic effects on the developing 
brain, contributing to ASD. A common example is 
phenylketonuria, an autosomal recessive condition leading to 
excessive phenylalanine levels, mental retardation and ASD, 
if not diet-controlled. Other related conditions include purine 
metabolism errors (adenylosuccinase deficiency and 
adenosine deaminase deficiency), creatine deficiency 
syndromes, Smith-Lemli-Opitz syndrome, biotinidase 
deficiency and histidinemia. Early screening and treatment 
of these conditions may have a positive impact in preventing 
disease progress. For example, the prevalence of individuals 
affected with phenylketonuria has decreased from 20% to 
6% with early detection during infancy and dietary 
intervention to control phenylalanine intake [28, 29]. Once 
mitochondrial abnormalities are better elucidated, similarly 
preventive intervention may become available. 
  Mitochondria are intracellular organelles in the 
cytoplasm known as the power houses of the cell. They play 
a crucial role in adenosine 5’-triphosphate (ATP) production 
through oxidative phosphorylation (OXPHOS). The latter 
process is carried out by the electron transport chain made up 
of  Complex I (NADH: Ubiquinone oxidoreductase or 
dehydrogenase), Complex II (Succinate:Ubiquinone 
oxidoreductase), Complex III (Coenzyme Q:Cytochrome c 
reductase or cytochrome bc1 complex), and Complex IV 
(Cytochrome c oxidase) required to convert food sources to 
cellular energy. The electron transport system is situated in 
the inner membrane of the mitochondria and contains 
proteins encoded by both nuclear and mitochondrial DNA 
[30]. About 100 proteins coded by both mitochondrial and 
nuclear genes are required for assembly of the complexes for 
the respiratory chain [31, 32]. The mitochondrial genome 
encodes 13 of these 100 proteins [33] (see Fig. 1). 
  Human mitochondrial DNA (mtDNA) is a circular 
double stranded DNA molecule contained within the 
mitochondrion and inherited solely from the mother. The 
evolutionary antecedents are bacterial plasmids. Each 
mitochondrion contains 2-10 mtDNA copies organized into 
nucleoids [33]. This organization is important to carry out 
segregation, replication and transcription of mtDNA [33, 
Fig. (1). Mitochondrial Structure and Function. 
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34]. In humans, 100-10,000 separate copies of mtDNA are 
usually present per cell, although an ovum contains about 
50,000-5,000,000 mitochondria [33-35] each containing 
mtDNAs, while sperm cells only have about 50-100 
mitochondria each.  
  Mitochondria are dynamic organelles that fuse and 
produce fission by changing shapes and size throughout the 
life of the cell. Thus far, the mitochondria cannot yet be 
accurately quantified but mtDNA can be analyzed. In 
mammals, each double-stranded circular mtDNA molecule 
consists of 15,000-17,000 base pairs containing a total of 37 
genes (for production of 13 oxidative phosphorylation 
proteins used to generate ATP, 22 genes for transfer RNA 
and two for ribosomal RNA) (see Fig. 2). When a mutation 
arises in a cellular mtDNA, it creates a mixed intracellular 
population of mutant and normal molecules known as 
heteroplasmy. When a cell divides, it is a matter of chance 
whether the mutant mtDNAs will be partitioned into one 
daughter cell or another. Therefore, over time, the percentage 
of mutant mtDNAs in different cell lineages can drift toward 
either pure mutant or normal (homoplasmy), a process 
known as replicative segregation, which then impacts on 
cellular energy and human diseases [36-38].  
  Mitochondrial disorders may present in early childhood 
or later in life. Human mitochondrial diseases due to 
homoplasmy for all mutant mtDNA copies often present 
early in childhood. Heteroplasmy may involve only a few 
mutant copies with the remaining copies being unaffected. 
Individuals with heteroplasmic mutational disorders may not 
display symptoms until adulthood or after many cell 
divisions, whereby a threshold number of abnormal 
mitochondria with mutant alleles result in disease. The 
disease Neuropathy with muscle weakness, Ataxia, and 
Retinitis Pigmentosa (NARP) is caused by T8993G 
heteroplasmic mtDNA mutations. When heteroplasmy is 
present in less than 10 percent of copies, NARP findings are 
usually absent. At 10-70 percent, adult onset NARP is 
present, and at 70-100 percent childhood Leigh syndrome 
occurs. Other examples of known mitochondrial diseases 
include Myoclonic Epilepsy with Ragged Red Fibers 
(MERRF) and the disorder known as Mitochondria 
Encephalomyopathy, Lactic Acidosis, and Stroke-like 
episodes (MELAS) (summarized by Wallace [37, 38]).  
  In the mitochondria ATP production, free oxygen 
radicals and reactive oxygen species (ROS) are produced and 
then normally removed from the cells by anti-oxidant 
enzymes. When the production of ROS and free radicals 
exceeds the limit, oxidative stress occurs, that is, ROS 
combine with lipids, nucleic acids and proteins in the cells 
leading to cell death by apoptosis or necrosis [39]. Since 
brain cells have limited antioxidant activity, a high lipid 
content and high requirement for energy, it is more prone to 
the effects of oxidative stress [40].  
  Coleman and Blass in [41] were the first to link to 
bioenergy metabolism disturbances with ASD. They 
reported lactic acidosis in four children with autism. Later, 
Laszlo  et al. [42] reported increased serotonin, lactic acid 
and pyruvate levels in children with autism. Lombard [43] 
then proposed that mitochondrial oxidative phosphorylation 
defects could cause abnormal brain metabolism in children 
with autism, leading to lactic acidosis and decreased serum 
carnitine levels. Conversely, Correia et al. [44] studied 196 
children with autism and found that 17% had high lactic acid 
levels and 53 had an elevated lactate to pyruvate ratio. 
Additionally, muscle biopsies performed in 30 of the 
children with autism showed a mitochondrial defect in 7 of 
the children. Muscle biopsies studied by Tsao and Mendell 
[45] in two unrelated girls with autism showed partial 
complex I deficiency and coenzyme Q10 deficiency in one 
girl and partial deficiency of complexes II, III and IV in the 
other. Both girls had normal serum amino acids, ammonia, 
lactate, urine organic acids and normal karyotyes as well as 
negative DNA studies for Rett and fragile X syndromes.  
  Recently, Shoffner and colleagues [46] studied 28 
children diagnosed with ASD for mitochondrial diseases and 
found high levels of lactate, pyruvate and alanine in the 
blood, urine and cerebrospinal fluid in 14 of the children. 
Using muscle biopsies, they identified a mitochondrial 
complex I defect in 50% (14/28) of the affected children, 
combined complex I and III defects in 18% (5/28), combined 
complex I, III and IV defects in 18% (5/28) and isolated 
complex V defects in 14% (4/28). Seventy-one percent 
(20/28) of the children had abnormal oxidative 
phosphorylation after performing protein assessment studies 
on selected subunits for complexes I, II, III and IV. Their 
results suggested an even greater link between ASD and 
impairment in mitochondrial function. (see Table 1 for a 
summary of known mitochondrial and nuclear gene defects 
in ASD).  
Mitochondrial Gene Defects  
  Early cases reported by Graf and colleagues [47] provide 
examples of mtDNA mutations and enzyme defects. They 
described a brother and sister with mtDNA G8363A transfer 
Fig. (2). Linear Model of the Mitochondrial DNA Molecule.
Linear model of mitochondrial DNA
** *    +
- Twenty-two genes encoding transfer RNA - One gene encoding complex III - Three genes encoding complex IV + *
ATPase 8 ATPase 9 COIII ND3 ND4L ND4 ND5 ND6 Cyt b D Loop 12s rRNA 16s rRNA ND1 ND2 COI COII
- Two genes encoding ribosomal RNA - Seven genes encoding complex I - Two genes encoding complex V
ND: NADH dehydrogenase, Cyt b: Cytochrome bl, CO: Cytochrome c oxidase
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Table 1.  Reports of Autism Spectrum Disorders (ASD) Involving Mitochondrial and Nuclear Gene Defects 
References 
Number of 
Subjects 
with ASD 
Sample 
Mitochondrial  
Complex Defects 
Mitochondrial  
Gene Defects 
Nuclear Gene Defects  Other 
Laszlo et al.,
1994
30 Blood     
Chromosome 18q deletion 
(1 of 30 subjects) 
LA  (13 of 30 subjects); 
Pyruvate  (9 of 30 
subjects) 
Graf et al., 
2000
1
Blood, 
Muscle 
I, IV 
tRNALys  
(G8363A) 
Fillano et al., 
2002
12 Muscle 
I, III, IV, V (7 of 
8 subjects) 
mtDNA deletion (5 of 
12 subjects); 
mtDNA defect (3 of 12
subjects) 
Filipek et al., 
2003
2 Muscle  III   
Chromosome 15q11-q13 
duplication  
(2 of 2 subjects) 
Carnitine  (2 of 2 
subjects); 
Plasma alanine  (1 of 2 
subjects);  
Lactate  (1 of 2 subjects); 
CPK  (1 of 2 subjects) 
Pons et al.,
2004
5  Muscle  I, II, III, IV 
tRNALeu (A3243G)  
(2 of 5 subjects) 
Plasma lactate  (2 of 3 
subjects);  
CSF lactate  (1 of 1 
subject) 
Ramoz et al.,
2004
411 Blood     
SNP (rs2056202 and 
rs2292813) 
in SLC25A12 of 
chromosome 2q31 
(197 of 411 subjects) 
Oliveira et 
al., 2005 
69  Muscle  I, IV, V  No mutations seen   
Plasma lactate  (14 of 69 
subjects) 
Segurado et 
al., 2005 
174
Blood,  
Buccal 
cells 
SNP (rs2056202 and 
rs2292813) 
in SLC25A12 (158 of 174 
subjects) 
Correia et al.,
2006
210 Muscle 
Multiple complex 
defects 
 Normal  SLC25A12 LA   (36 of 210 subjects) 
Tsao & 
Mendell, 
2007
2  Muscle  II, III, IV   
SNP (rs2056202 ) in 
SLC25A12
CoQ10 deficiency (1 of 2 
subjects) 
Weissman et 
al., 2008 
25
Blood, 
Muscle 
I (16 of 23 
subjects),  
II (2 of 23 
subjects), 
 III (5 of 23 
subjects),  
IV (1 of 23 
subjects) 
mtDNA deletion  
(7 of 25 subjects) 
Plasma lactate  (19 of 25 
subjects); Plasma pyruvate 
 (9 of 17 subjects); 
Plasma CPK  (8 of 25 
subjects) 
Silverman et 
al., 2008 
355 Blood     
SNP (rs2056202 and 
rs2292813) 
in SLC25A12 (170 of 355 
subjects) 
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(Table 1). Contd….. 
References 
Number of 
Subjects 
with ASD 
Sample 
Mitochondrial  
Complex Defects 
Mitochondrial  
Gene Defects 
Nuclear Gene Defects  Other 
Shoffner et 
al., 2010 
28
Muscle, 
Blood 
CSF, 
Urine 
I (14 of 28 
subjects);  
I+III (5 of 28 
subjects); 
 V (4 of 28 
subjects); 
I+III+IV (20 of 28
subjects) 
mtDNA deletion  
(1 of 20 subjects) 
Plasma lactate ;
CoQ10 deficiency (1 of 14
subjects) 
Giulivi et al., 
2010
10 Blood 
Decreased NADH
oxidase (8 of 10 
subjects); 
I (6 of 10 
subjects);  
IV (3 of 10 
subjects);  
V (4 of 10 
subjects) 
mtDNA over-
replication (5 of 10 
subjects); 
Cytochrome b1 gene 
deletion (2 of 10 
subjects) 
Succinase oxidase (6 of 10
subjects); 
Pyruvate dehyrogenase (8 
of 10 subjects) 
Ezugha et al.,
2010
1   I,  IV   
1Mb deletion in 
chromosome 5q14.3 
CPK = creatine phosphokinase; LA = lactic acidosis; CSF = cerebral spinal fluid.
RNA (tRNAlys) mutations. The 3 year old boy met the 
diagnostic criteria for autism at 4 years of age and showed a 
60% mutation rate in muscle tissue and 61% in blood. His 
mitochondrial markers of lactate and pyruvate levels were 
normal following a carbohydrate loading test. The activity of 
the mitochondria respiratory chain (MRC) was measured for 
complexes I, II, III, IV and citrate synthetase. This boy had 
high activity for mitochondrial enzyme levels suggested by 
ratios of complex I to citrate synthetase, but normal activity 
for complexes II, III and IV. His sister at age 6 years was 
diagnosed with Leigh syndrome, a neurometabolic disorder 
affecting the brain and manifesting between 3 months and 2 
years of age due to mutations of mtDNA or nuclear genes 
involving mainly complex I. She was found to have the same 
mtDNA mutation but present at an 86% level in the muscle 
and 82% in blood, with increased lactate levels and low 
mitochondrial enzyme activity. This study of G8363A 
mtDNA mutations in autism stresses the importance of 
biochemical mitochondrial markers and mtDNA mutations 
requiring further investigations.  
  In addition, Pons et al. [48] followed five unrelated 
children with ASD and reported abnormal respiratory chain 
enzyme activity. A mtDNA gene mutation at position 
A3243G was found in four of the five children. High 
cerebral lactic acid levels were identified using brain 
magnetic resonance spectroscopy in three of the five 
subjects. One child with ASD had an older sister with the 
mtDNA deletion syndrome (MDS), that is, a decreased 
quantity of mtDNA with a reduced number of mtDNA 
molecules per cell. MDS is an autosomal recessive disorder 
characterized by a quantitative defect in the copy number or 
amount of mtDNA and recently linked to two nuclear genes, 
dGK and TK2. The sister had no depletion of the mtDNA or 
mutations in the two nuclear genes. However, they did have 
mtDNA depletion in the skeletal muscle at a 72% level. 
These findings highlight the importance of the A3243G 
mtDNA mutation in ASD and the investigators proposed that 
mutations or depletion of mtDNA should be investigated in 
other children presenting with ASD. 
 Oliveira  et al. [49] reported to date the only population-
based ascertainment of children with ASD and mitochondrial 
dysfunction. They identified high lactate levels in 14 of 69 
children with ASD. High lactate-to-pyruvate level ratios 
occurred in 11 of the 14 children; deltoid muscle biopsies 
were performed in the 11 children for respiratory chain 
abnormalities. Point mutations were examined in the mtDNA 
at positions G8363A, A3243G, T3271C, T3256C, and 
T8356C, as well as mtDNA levels or depletions. While 5 of 
the 11 children showed definite mitochondrial respiratory 
disorders, using the clinical and laboratory diagnostic criteria 
reported by Bernier et al. [50], but no mtDNA genetic 
defects were observed. Later, Oliveira et al. [51] reported on 
genetic and associated medical conditions occurring in 
children with ASD and showed 5 percent with chromosome 
disorders, 4 percent with mitochondrial disorders, 3 percent 
with single gene disorders, 3 percent with infectious 
diseases, 3 percent with genomic syndromes or birth defects 
and the remaining cases having idiopathic (unknown) causes. 
Their study further confirmed the role of the electron 
transport chain in the mitochondria and autism. Although 
they did not find large deletions in the mitochondrial DNA, 
lack of analysis for microdeletions, mutations and depletion 
of mtDNA were limitations of the study. 
  An interesting study by Fillano et al. [52] further 
illustrates the importance of the mitochondria in children 
with features of ASD. They evaluated 12 children with 328 Current Genomics, 2011, Vol. 12, No. 5 Dhillon et al.
HEADD syndrome (hypotonia, epilepsy, autism and 
developmental delay) for mitochondrial abnormalities by 
examining electron transport chain respiratory activity, 
mitochondrial structure and deletions or point mutations of 
mtDNA genes or the amount of mtDNA present. They 
documented decreased activity of the mitochondrial 
respiratory complexes (I, III, IV and V) mainly in enzymes 
encoded by mtDNA, in seven of eight subjects studied. 
However, seven individuals had normal mitochondrial 
structure while five had decreased or depleted amounts of 
mtDNA. Lastly, structural defects in the mitochondria were 
found in three of the four subjects studied. Interestingly, 
seven children with mitochondrial enzyme defects had no 
mutations or structural defects in the mitochondria and only 
one child with a mutation had no enzyme defects. Thus, it is 
too preliminary to hypothesize that enzyme defects are 
independent of mtDNA mutations or structural defects. The 
presence of enzyme defects at a later age is unknown. More 
studies are required to follow these children into later life. In 
this study, mtDNA point mutations were not seen although a 
7.4kb mtDNA mutation was observed in a child. Later, Pons 
et al. [48] found that 72% of the mtDNA genome was absent 
or depleted in a child with PDD having a history of mtDNA 
depletion syndrome in an older sister. The use of newer 
genetic techniques such as mtDNA microarrays and 
sequencing along with related nuclear genes (coding and 
non-coding RNA) will be useful to characterize the 
mitochondrial genome for depletion status or mutations.  
Relationship of Nuclear Genes 
  Studies reviewed by Smith et al. [53] linked nuclear 
genes and mtDNA in ASD, for example, the nuclear gene, 
SLC23A12. This most important gene located on 
chromosome 21q31 encodes a calcium-binding carrier 
protein used by the mitochondria. It is involved in the 
exchange of the amino acid aspartate for glutamate in the 
inner membrane of the mitochondria for use in the electron 
transport chain. Ramoz et al. [54] identified two single 
nucleotide polymorphisms (SNPs-rs2056202 and rs2292813) 
in the SLC25A12 gene associated with ASD in their study of 
411 families. This association was confirmed by Seguarado 
et al. [55] and by Silverman et al. [56]. 
  A recent study by Ezugha et al. [57] of a 12-year old 
male with dysmorphic facies, intellectual disability, autism, 
epilepsy and leg weakness identified decreased activity of 
mitochondrial complexes I and IV. A 1 Mb deletion was 
found on chromosome 5q14.3 band. They suggested that the 
features seen in this child were consistent with mitochondrial 
dysfunction and a nuclear gene is located on chromosome 5 
coding for protein involved in activity of these mitochondrial 
complexes. Correia et al. [44] also studied the linkage of this 
gene in an additional 241 families and found high lactate 
levels and lactate/pyruvate ratios. However, they did not find 
SNPs for the SLC23A12 gene in their families with autism. 
Also, Chien et al. [58] studied 465 individuals with ASD but 
did not find any SNP changes in the SLC23A12 gene. 
Role of the Nuclear Genome in Mitochondrial DNA 
Replication, Maintenance and Depletion 
  Mitochondrial DNA replication and maintenance is 
regulated by enzymes which are proteins encoded by nuclear 
DNA genes [59]. One such nuclear gene is DNA polymerase 
gamma 1 (POLG1) which codes for mitochondrial DNA 
polymerase [60]. This gene is involved in the production of 
mtDNA and has been linked to various mitochondrial 
conditions. Therefore, mutations in nuclear genes required 
for mtDNA replication may affect mtDNA function.  
  Studies have examined the role of nuclear genes in 
causing depletion of the mtDNA genome and tissue specific 
conditions [61, 62]. Mandel and colleagues [61] observed 
neuronal symptoms with increased lactic acid levels in 19 
children with deoxyguanosine kinase dGUOK gene 
mutations and hepatic failure with reductions in activity of 
mitochondrial complexes I, II and IV. However, the enzyme 
activity for complex II, which is encoded by nuclear DNA, 
was normal in these patients. Furthermore, quantitative 
mtDNA analysis showed a reduced mtDNA/nuclear DNA 
ratio of 8-39% in liver specimens from seven of the children.  
  The main supply for dNTPs required for energy comes 
from the deoxynucleoside salvage pathway regulated by two 
mitochondrial enzymes dGK and TK2, encoded by the 
nuclear genome [63, 64]. Hence, Mandel et al. [61] 
examined nuclear genes and found that dGK was mutated in 
patients with reduced mtDNA/nuclear DNA ratios. A similar 
study by Saada et al. [62] in two of four individuals with 
known mitochondrial depleted myopathy showed a mutation 
in the TK2 nuclear gene. These two studies further supported 
that nuclear genes are linked to mtDNA but more research is 
needed to determine their role in autism and for 
identification of mtDNA genetic defects, mutations or for the 
mtDNA depletion status associated with related nuclear 
genome defects. 
  Polymerase gamma (POLG1) is an important polymerase 
enzyme responsible for mtDNA replication and base 
excision repair [60]. The nuclear gene encoding the POLG1 
enzyme is located on chromosome band 15q25 [65, 66]. Any 
mutation in this gene will impact mtDNA replication and 
repair processes. Interestingly, in humans, maternal disomy 
15 (both chromosome 15s from the mother) is seen in about 
25% of subjects with Prader-Willi syndrome (PWS), the 
most common known syndromic cause of morbid obesity in 
humans [67]. PWS is frequently associated with ASD 
particularly in those subjects with PWS due to maternal 
disomy 15 and associated with a lower metabolic rate [68]. 
Therefore, maternal disomy 15 in PWS could also influence 
the activity of the POLG1 gene. Studies have shown that 
mutations or disturbances of the POLG1 gene cause 
deletions of mtDNA genes. Additionally, autism is linked to 
defects of human chromosome 15q11-q13 region including 
inverted duplications found in about 5% of cases with autism 
[12]. Filipek et al. [69] further reported that subjects with 
15q11-q13 duplications and ASD have increased 
mitochondria and mitochondrial respiratory chain blockage 
at complex IV, but lactate levels were not significantly 
elevated. While this study did not examine for mtDNA 
mutations, it established a link between genes in the nucleus 
specifically on chromosome 15q11-q13 and an interplay 
with mitochondrial function in subjects with autism. 
 Van  Goethem  et al. [70] showed that autosomal 
dominant progressive external opthalmoplegia (adPEO) is 
due to POLG1 gene mutations leading to mtDNA deletions. Mitochondria and Autism  Current Genomics, 2011, Vol. 12, No. 5    329
Apart from POLG1, the autosomal dominant type of PEO 
has been linked to the TWINKLE gene on chromosome 10q 
[35] and the ANT1 gene on chromosomal 4q [71]. These 
nuclear gene mutations are known to cause mtDNA 
disturbances. 
 POLG1 has been linked to many conditions apart from 
adPEO. For example, it causes autosomal recessive PEO, 
sensory-ataxic neuropathy, dysarthria and opthalmoplegia 
(SANDO), juvenile spino-cerebellar ataxia-epilepsy 
syndrome (SCAE) and Alpers-Huttenlocher hepatopathic 
poliodystrophy. These encephalomyopathies are caused by 
abnormal nuclear mitochondrial intergenomic cross-talk 
linked to POLG1 gene mutations and to mtDNA deletions. 
This strong link between nuclear genes and the mtDNA 
genome is further supported by a prevalence of 2% of 
individuals in the general population carrying this nuclear 
gene defect [59].  
  Another nuclear gene that can cause multiple mtDNA 
abnormalities including duplications, deletions and point 
mutations is thymidine phosphorylase (TP) [72, 73]. The TP 
nuclear gene is located on chromosome 22q13 [74] and 
encodes the cytosolic enzyme regulating pyrimidine 
nucleoside levels through phosphorolytic thymidine 
catabolism to thymidine and ribose [75]. Mitochondria 
neurogastrointestinal encephalopathy (MNGIE) results from 
loss of TP activity. Hence, the above studies have shown that 
mutations of nuclear genes TK2, DGK, PLOG, TWINKLE, 
ANT1 and TP can cause deletions and depletions of mtDNA, 
their involvement and frequency in ASD requires further 
investigation. 
  Finally, oxidative stress and gene methylation 
(epigenetics) are both considered to play a role in producing 
ASD. Oxidative stress in brain cells due to genetic or 
environmental causes, leads to decreased methionine 
synthase activity [76]. Methionine synthase action involves 
two processes: a) dopamine-stimulated phospholipid 
methylation which is required for synchronizing normal 
brain activity during attention; and b) DNA methylation 
which silences gene activity. During DNA methylation a 
methyl group is added to the cytosine-phosphate-guanine 
(CpG) site and the methylated cytosine is converted to 5-
methylcytosine; thus, inactivating gene expression. This is a 
normal process. One can propose that the important 
interaction between methionine metabolism and methylation 
with overall reactions of folate and B12 metabolism is 
regulated by mitochondrial reduction/oxidative reactions 
controlling nuclear gene methylation (epigenetics or 
methylomics) and glutathione metabolism. When disturbed, 
this process contributes to ASD [77]. When methionine 
synthase activity is impaired, children may manifest 
attentional impairment and other symptoms from defective 
gene expression leading to ASD.  
 Deth  et al. [78] further reported the involvement of 
various genes in the process of methylation with the most 
important being methyl-CpG-binding (MeCP2) protein. 
Abnormal MeCP2 protein is linked to Rett syndrome and 
ASD [79]. MeCP2 participates in gene silencing by binding 
to the methylated genes in the brain. Any mutation of this 
gene impacts on the expression status of known methylated 
genes and therefore interferes with epigenetics.  
  Oxidative stress is also known to cause deletions of the 
mtDNA genes in mice models [80]. For example, 
chronically-administered intraperitoneal injections of the 
chemotherapeutic agent, doxorubicin, in mice has resulted in 
a 4kb deletion of the mtDNA in heart muscle. In addition, Lu 
et al. [81] indirectly confirmed these findings by reporting 
mtDNA deletions in ageing skin from humans with increased 
free oxygen radicals and reactive oxygen species and further 
support the basis for examining mtDNA or gene deletions in 
ASD.    
  To further evaluate for mitochondrial dysfunction and 
mtDNA abnormalities, Giulivi et al. [82] recently studied 
lymphocytes from 10 children with ASD and 10 controls 
aged 2 to 5 years. The outcome measures included oxidative 
phosphorylation capacity at the cell level, mtDNA copy 
number, mitochondrial rate of hydrogen peroxide 
production, and plasma lactate and pyruvate levels. The 
majority of the children with ASD (6 of 10) had lower 
mitochondrial complex I activity than found in controls. 
Higher plasma pyruvate levels occurred in 8 of 10 children 
with ASD compared with controls consistent with a lower 
pyruvate dehydrogenase activity. Hence, children with ASD 
had higher mitochondrial rates of hydrogen peroxide 
production than in controls. Mitochondrial genome studies 
showed mitochondrial DNA overreplication in 5 children 
with ASD and mtDNA deletions involving the segment 
coding for cytochrome b in 2 children with ASD. Therefore, 
the children with ASD were more likely to have 
mitochondrial dysfunction, mtDNA overreplication, and/or 
mtDNA deletions than typically developing children. 
  In summary, the role of the mitochondria and 
mitochondrial defects are discussed in relationship to ASD. 
Several studies have linked autism to defects in oxidative 
phosphorylation encoded by mtDNA along with interaction 
of nuclear genes. Individuals with the ASD phenotype 
clearly show genetic-based primary mitochondrial disease. 
Further studies with the latest genetic technology such as 
next generation sequencing, microarrays, bioinformatics and 
biochemical assays will be required to determine the 
prevalence and type of mitochondrial defects in ASD. 
Elucidation of molecular abnormalities resulting from 
mitochondrial or genetic defects in individuals with ASD 
may lead to better treatment options and outcomes. 
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